Saliva

PreclinicalBiologic

VVersailles Hospital

Saliva is one of 9 biologic programs targeting Clostridium Difficile Infection. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Clostridium Difficile InfectionActive, not recruiting

Clostridium Difficile InfectionPreclinical

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Clostridium Difficile Infection

#DrugCompanyPhaseTrials

Dificlir

Merck & Co.

Approved

10 2

Vancocin

HHikma Pharmaceuticals LLC

Approved

21 3

ZINPLAVA

Merck & Co.

Approved

4 4

Prilosec

DDexcel Pharma Technologies Ltd.

Whole Blood

1 6

Serum

VVersailles Hospital

Preclinical

1 7

Stools

VVersailles Hospital

Preclinical

1 8

Vancomycin or Fidaxomicin

SSejtterapia Kozpont Kft.

Preclinical

1 9

Saliva

VVersailles Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Clostridium Difficile Infection1 trial

Predictive Value of the Immune Response of the Host in Clostridium Difficile Infections

Completed·VVersailles Hospital·N/A·NCT01946750·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Saliva. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Saliva compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Saliva. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Versailles Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: VVersailles Hospital

Saliva

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Clostridium Difficile Infection1 trial

References

Drug Info

Quick Facts

Related News